ClinicalTrials.gg
TerminatedNCT07242781Updated Jul 20, 2026

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

A Phase 1 interventional study of BMS-986365 and Itraconazole in Healthy Volunteers, sponsored by Celgene. Terminated at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the effect of Itraconazole and Rifampin on the drug levels of AR-LDD (BMS-986365) in healthy adult male participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy male volunteers
  • BMS-986365
  • CC-94676
  • Itraconazole
  • Rifampin
  • Pharmacokinetics
  • Crossover
  • Open-label
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be male, at the time of signing the Form (ICF), have a (BMI) of 18.0 to 32.0 kg/m2; and healthy as determined by medical history, PE, vital signs, 12-lead , transthoracic echocardiogram (TTE) and clinical laboratory assessments.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any significant or chronic illness.
  • Participants must not have a prior history of heart failure, ischemic heart diseases, serious cardiac arrythmias, or prolonged .
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Part A (Safety Lead-in Group)

    Drug: BMS-986365 · Drug: Itraconazole

  • Experimental
    Part A, Period 1

    Drug: BMS-986365

  • Experimental
    Part A, Period 2

    Drug: BMS-986365 · Drug: Itraconazole

  • Experimental
    Part B, Period 1

    Drug: BMS-986365

  • Experimental
    Part B, Period 2

    Drug: BMS-986365 · Drug: Rifampin

Interventions

  • Specified dose on specified days

    Also known as: AR-LDD, CC-94676

  • Specified dose on specified days

    Also known as: SPORANOX®

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of BMS-986365

    Time frame: Up to approximately Day 32

  2. Part A: Cmax of BMS-986365 Without Itraconazole

    Time frame: Up to approximately Day 32

  3. Part A: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986365 With Itraconazole

    Time frame: Up to approximately Day 32

  4. Part A: AUC(0-T) of BMS-986365 Without Itraconazole

    Time frame: Up to approximately Day 32

  5. Part A: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-986365

    Time frame: Up to approximately Day 32

  6. Part A: AUC(INF) of BMS-986365 Without Itraconazole

    Time frame: Up to approximately Day 32

  7. Part B: Cmax of BMS-986365 With Rifampin

    Time frame: Up to approximately Day 37

  8. Part B: Cmax of BMS-986365 Without Rifampin

    Time frame: Up to approximately Day 37

  9. Part B: AUC(INF) of BMS-986365 With Rifampin

    Time frame: Up to approximately Day 37

  10. Part B: AUC(INF) of BMS-986365 Without Rifampin

    Time frame: Up to approximately Day 37

  11. Part B: AUC(0-T) of BMS-986365 With Rifampin

    Time frame: Up to approximately Day 37

  12. Part B: AUC(0-T) of BMS-986365 Without Rifampin

    Time frame: Up to approximately Day 37

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately Day 89

  2. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to approximately Day 89

  3. Number of Participants With AEs Leading to Drug/Study Discontinuation

    Time frame: Up to approximately Day 89

  4. Number of Participants With Clinically Significant Vital Sign Measurements

    Time frame: Up to approximately Day 77

  5. Number of Participants With Clinically Significant Laboratory Safety Tests

    Laboratory safety tests include hematology, chemistry, and urinalysis.

    Time frame: Up to approximately Day 77

  6. Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Abnormalities

    Time frame: Up to approximately Day 77

  7. Number of Participants With Clinically Significant Physical Examination (PE) Abnormalities

    Time frame: Up to approximately Day 77

  8. Change From Baseline of Corrected QT Interval (QTc) Post Dose of BMS-986365

    Time frame: Up to approximately Day 77

  9. Part A: Change From Baseline of QTc Post Dose of BMS-986365 With Itaconazole

    Time frame: Up to approximately Day 72

  10. Part B: Change From Baseline of QTc Post Dose of BMS-986365 With Rifampin

    Time frame: Up to approximately Day 77

  11. Time of Maximum Observed Plasma Concentration (Tmax) of BMS-986365

    Time frame: Up to approximately Day 77

  12. Apparent Terminal Plasma Half-life (T-HALF) of BMS-986365

    Time frame: Up to approximately Day 77

  13. Apparent Total Body Clearance (CLT/F) of BMS-986365

    Time frame: Up to approximately Day 77

  14. Apparent Volume of Distribution of Terminal Phase (Vz/F) of BMS-986365

    Time frame: Up to approximately Day 77

07

Study locations

1 site
  • Local Institution - 0001
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Apr 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Dec 15, 2025
Primary completionActual
Apr 9, 2026
CompletionActual
Apr 21, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07242781
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Dec 15, 2025
Primary completion
Apr 9, 2026
Completion
Apr 21, 2026
Last update
Jul 20, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dezandrodeg

Start the discussion